Replies to post #791725 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Love this development Lykiri. It took longer to develop and implement but the paid off is huge. This new system can help the scale up to reach more patients and accross borders. I believe too regulators prefer this digital systems more than others such as google sheet for example.

[seekinganswers]

Yes yes yes..
I hear that FDA is going to give them all the money needed to buy Merck, Johnson and Johnson and Eli Lilly.
I also heard the United Nations and the World Health Organization are chipping in to make NWBO a sovereign Country in its own right for the world to recognize. Amazing times for this 24 cent, broke Bulletin Board stock.

[Investor082]

Is the conviction similar to $22+ share price forecast for 2022, and May 2025 UK approval? ;)

[dennisdave]

Thank you Lykiri

The October 6 2025 CGT Catapult Autolomous white paper might actually tell us why MHRA has taken so long with DCVaxL.
The project, funded by UK Research & Innovation, validated a fully digital GMP environment using Autolomous’ autolomate platform showing a 65 % faster QA review, near-zero data-entry errors, and complete paper-elimination in a real MHRA-licensed facility. Advent Bio/Sawston manufactures DCVax-L on that same digital infrastructure. So the MHRA hasn’t just been reviewing a therapy; they’ve been validating the entire digital manufacturing backbone that will define how future autologous cell therapies are regulated in the UK.

If thats the case, and Im personally 95% sure now then this was never just about GBM efficacy it’s about system-building.
Murcidencel/DCVax-L is the pilot case for embedding digital GMP and data-integrity standards into UK regulation.
Now that this government-backed validation is public, MHRA finally has everything it needs to close the review.